RecruitingPhase 3NCT06291207
A Study to Evaluate the Efficacy and Safety of AD-224
A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients with Essential Hypertension
Sponsor
Addpharma Inc.
Enrollment
252 participants
Start Date
Apr 15, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-224
Eligibility
Min Age: 19 Years
Inclusion Criteria3
- Signed informed consent
- Patients with Essential Hypertension
- Other inclusions applied
Exclusion Criteria2
- Patient with Secondary Hypertension
- Other exclusions applied
Interventions
DRUGAD-224A
PO, Once daily, 8weeks
DRUGAD-224B
PO, Once daily, 8weeks
DRUGAD-224C
PO, Once daily, 8weeks
DRUGPlacebo of AD-224A
PO, Once daily, 8weeks
DRUGPlacebo of AD-224B
PO, Once daily, 8weeks
DRUGPlacebo of AD-224C
PO, Once daily, 8weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06291207
Related Trials
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT0605963898 locations
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
NCT045056181 location
Mobile Health Program for Rural Hypertension
NCT055469311 location
The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature
NCT050679981 location
An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ
NCT054130571 location